SCHEMBL5243063

SCHEMBL5243063

COc1ccc(S(=O)(=O)N2CCCC(C(=O)O)C2)cc1

nearest known ligand 0.74

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.74
TSHR P16473 1/20 0.71
MAPT P10636 1/20 0.70
NPC1 O15118 1/20 0.67
LMNA P02545 2/20 0.65
AKR1C3 P42330 4/20 0.65
HTT P42858 2/20 0.64
GAA P10253 2/20 0.64
KDM4E B2RXH2 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
HSD17B10 Q99714 1/20 0.64
AKR1C1 Q04828 1/20 0.63
USP2 O75604 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclohexylamine SCHEMBL6003299 0.92 TSHR (0.69) ALDH1A1TSHRMAPTNPC1LMNA
SCHEMBL29873927 0.89 ALDH1A1 (0.73) ALDH1A1TSHRNPC1LMNAHTT
SCHEMBL7700065 0.85 AKR1C3 (0.66) ALDH1A1MAPTLMNAAKR1C3HTT
SCHEMBL7308664 0.85 MAPT (0.76) ALDH1A1MAPTLMNAAKR1C3GAA
SCHEMBL25293495 0.85 MAPT (0.80) ALDH1A1TSHRMAPTLMNAAKR1C3
SCHEMBL12793334 0.85 MAPT (0.80) ALDH1A1TSHRMAPTLMNAAKR1C3
SCHEMBL19392388 0.85 MAPT (0.80) ALDH1A1TSHRMAPTLMNAAKR1C3
SCHEMBL7534615 0.84 ALDH1A1 (1.00) ALDH1A1TSHRNPC1LMNAHTT
SCHEMBL4799931 0.84 PKM (0.78) ALDH1A1TSHRMAPTNPC1LMNA
SCHEMBL4701073 0.84 MAPT (0.77) ALDH1A1TSHRMAPTLMNAAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1866285-A1 1-SULFONYL-PIPERDINE-3-CARBOXYLIC ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS F. Hoffmann-Roche AG (CH) 2007-12-19 EP claimed
WO-2006094633-A1 1- SULFONYL-PI PERDINE- 3 -CARBOXYL I C ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS F. HOFFMAN-LA ROCHE AG (CH) 2006-09-14 WO claimed
EP-1866285-A1 1-SULFONYL-PIPERDINE-3-CARBOXYLIC ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS F. Hoffmann-Roche AG (CH) 2007-12-19 EP disclosed
WO-2006094633-A1 1- SULFONYL-PI PERDINE- 3 -CARBOXYL I C ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS F. HOFFMAN-LA ROCHE AG (CH) 2006-09-14 WO disclosed
US-20060199816-A1 Aryl sulfonyl piperidines GILLESPIE PAUL 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199816-A1 Aryl sulfonyl piperidines GPR119, SLC5A2, GLS2 ALDH1A1 88/4885TSHR 761/4885MAPT 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.